Zimmer/TSL 6-Month Permacol Trial To Support 2004 Launch
This article was originally published in The Gray Sheet
Executive Summary
Zimmer expects to launch Tissue Science Laboratories' Permacol in the U.S. in the second half of next year for shoulder rotator cuff repair following a six-month trial to support marketing efforts
You may also be interested in...
Zimmer/Centerpulse Merger Would Build Minimally-Invasive Surgery Portfolio
Centerpulse's allogenic bone concentrate (ABC) would give Zimmer a spine fusion product to compete directly with Medtronic Sofamor Danek's InFuse bone graft/LT-CAGE lumbar tapered fusion device
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.